During the last session, Akero Therapeutics Inc. (NASDAQ:AKRO)’s traded shares were 0.49 million. At the end of the trading day, the stock’s price was $9.39, reflecting an intraday gain of 4.45% or $0.4. The 52-week high for the AKRO share is $30.53, that puts it down -225.13 from that peak though still a striking 9.27% gain since the share price plummeted to a 52-week low of $8.52. The company’s market capitalization is $333.91M, and the average trade volume was 234.76K shares over the past three months.
Akero Therapeutics Inc. (AKRO) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. AKRO has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.84.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Akero Therapeutics Inc. (AKRO) registered a 4.45% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.45% in intraday trading to $9.39 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -15.86%, and it has moved by -32.54% in 30 days. Based on these gigs, the overall price performance for the year is -66.71%.
The consensus price target of analysts on Wall Street is $48.00, which implies an increase of 80.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $26.00 and $62.00 respectively. As a result, AKRO is trading at a discount of -560.28% off the target high and -176.89% off the low.
Akero Therapeutics Inc. (AKRO) estimates and forecasts
Statistics show that Akero Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Akero Therapeutics Inc. (AKRO) shares have gone down -62.14% during the last six months, with a year-to-date growth rate less than the industry average at -13.15% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 2.30% this quarter and then drop -83.70% in the quarter after that.
While earnings are projected to return -14.90% in 2022, the next five years will return -14.60% per annum.
Akero Therapeutics Inc. is due to release its next quarterly earnings between March 14 and March 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akero Therapeutics Inc. (NASDAQ:AKRO)’s Major holders
Akero Therapeutics Inc. insiders own 22.57% of total outstanding shares while institutional holders control 89.13%, with the float percentage being 115.12%. Janus Henderson Group PLC is the largest shareholder of the company, while 162 institutions own stock in it. As of Sep 29, 2021, the company held over 3.23 million shares (or 9.27% of all shares), a total value of $72.3 million in shares.
The next largest institutional holding, with 2.69 million shares, is of Redmile Group, LLC’s that is approximately 7.70% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $60.06 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akero Therapeutics Inc. (AKRO) shares are ACAP Strategic Fund and Janus Henderson Global Life Sciences Fund. Data provided on Sep 29, 2021 indicates that ACAP Strategic Fund owns about 1.09 million shares. This amounts to just over 3.14 percent of the company’s overall shares, with a $24.47 million market value. The same data shows that the other fund manager holds slightly less at 1.01 million, or about 2.89% of the stock, which is worth about $22.5 million.